Johnson & Johnson $JNJ Shares Sold by Bessemer Group Inc.

Key Points

• Bessemer Group Inc. reduced its Johnson & Johnson stake by 3.7% in the fourth quarter, selling 29,584 shares and leaving it with 775,121 shares valued at about $160.4 million.
• Johnson & Johnson beat quarterly earnings and revenue estimates, reporting EPS of $2.70 on revenue of $24.06 billion, and raised its FY 2026 EPS guidance to $11.45-$11.65.
• The company increased its quarterly dividend to $1.34 per share from $1.30, while analysts remain broadly positive with a consensus Moderate Buy rating and average price target of $253.04.

Bessemer Group Inc. cut its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 3.7% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 775,121 shares of the company's stock after selling 29,584 shares during the period. Bessemer Group Inc.'s holdings in Johnson & Johnson were worth $160,410,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Cresta Advisors Ltd. acquired a new stake in shares of Johnson & Johnson during the 4th quarter worth $26,000. Abich Financial Wealth Management LLC acquired a new stake in shares of Johnson & Johnson during the 3rd quarter worth $26,000. DecisionPoint Financial LLC increased its holdings in shares of Johnson & Johnson by 104.2% during the 4th quarter. DecisionPoint Financial LLC now owns 147 shares of the company's stock worth $30,000 after buying an additional 75 shares during the last quarter. Bay Harbor Wealth Management LLC increased its holdings in shares of Johnson & Johnson by 49.0% during the 4th quarter. Bay Harbor Wealth Management LLC now owns 149 shares of the company's stock worth $31,000 after buying an additional 49 shares during the last quarter. Finally, Family CFO Inc acquired a new stake in shares of Johnson & Johnson during the 4th quarter worth $31,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $230.61 on Friday. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.03 and a quick ratio of 0.77. The firm has a 50-day moving average of $235.49 and a two-hundred day moving average of $221.76. The stock has a market cap of $555.13 billion, a P/E ratio of 26.66, a PEG ratio of 2.26 and a beta of 0.27. Johnson & Johnson has a 1-year low of $147.33 and a 1-year high of $251.71.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Tuesday, April 14th. The company reported $2.70 earnings per share for the quarter, beating analysts' consensus estimates of $2.68 by $0.02. The company had revenue of $24.06 billion during the quarter, compared to analysts' expectations of $23.60 billion. Johnson & Johnson had a net margin of 21.83% and a return on equity of 32.60%. The firm's revenue for the quarter was up 9.9% on a year-over-year basis. During the same period in the prior year, the company posted $2.77 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. On average, research analysts expect that Johnson & Johnson will post 11.57 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 9th. Shareholders of record on Tuesday, May 26th will be given a $1.34 dividend. This represents a $5.36 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date of this dividend is Tuesday, May 26th. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.30. Johnson & Johnson's dividend payout ratio is currently 60.12%.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Vanessa Broadhurst sold 6,197 shares of the company's stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $243.39, for a total value of $1,508,287.83. Following the completion of the transaction, the executive vice president directly owned 23,003 shares of the company's stock, valued at $5,598,700.17. This represents a 21.22% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Timothy Schmid sold 22,623 shares of the stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $244.33, for a total transaction of $5,527,477.59. Following the transaction, the executive vice president directly owned 26,769 shares in the company, valued at $6,540,469.77. The trade was a 45.80% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 30,142 shares of company stock valued at $7,360,528. 0.16% of the stock is currently owned by corporate insiders.

Key Headlines Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Leerink Partners upgraded Johnson & Johnson to Outperform and lifted its price target, citing stronger growth prospects from upcoming drug launches and broader oncology/immunology momentum. Article Title
• Positive Sentiment: New clinical and commercial updates around CAPLYTA, cardiology, Crohn’s disease, and robotics may support confidence in J&J’s innovation pipeline. Article Title
• Neutral Sentiment: J&J’s stock remains below some recent highs and has been consolidating after earnings, suggesting investors are still weighing valuation and execution. Article Title
• Negative Sentiment: A bladder-cancer survey highlighted the significant burden of current standard treatments, which may reinforce concerns about unmet needs and the pace of innovation in that area. Article Title

Analyst Upgrades and Downgrades

A number of research firms have recently commented on JNJ. The Goldman Sachs Group upped their price objective on Johnson & Johnson from $265.00 to $275.00 and gave the stock a "buy" rating in a report on Wednesday, April 15th. Argus upped their price objective on Johnson & Johnson from $240.00 to $275.00 and gave the stock a "buy" rating in a report on Thursday, April 16th. Bank of America upped their price objective on Johnson & Johnson from $253.00 to $254.00 and gave the stock a "neutral" rating in a report on Wednesday, April 15th. Citigroup increased their price target on Johnson & Johnson from $274.00 to $285.00 and gave the company a "buy" rating in a report on Tuesday, April 7th. Finally, Scotiabank reiterated an "outperform" rating on shares of Johnson & Johnson in a report on Thursday, January 22nd. Twenty analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $253.04.

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.